Vertex to Acquire Crinetics for $10 Billion, Boosting Pipeline and Revenue
VRTX sits 43% above its 52-week low of $362.5.
Summary
Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $10 billion in cash, equating to $85 per share. This strategic acquisition is set to significantly expand Vertex's pipeline into endocrine diseases, with the potential to add $5 billion in annual revenue to its current $12 billion base. Crinetics shares more than doubled following the news, reflecting the substantial premium offered. To facilitate the transaction, Vertex has secured $4.5 billion in bridge financing. The acquisition, which builds on Vertex's recent positive regulatory momentum, is expected to close in the third quarter of 2026.
At the time of this announcement, VRTX was trading at $517.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.4B. The 52-week trading range was $362.50 to $529.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.